Ontrak (OTRK) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 28, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CATASYS, INC.	'
Document Type	'10-K	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	20,559,712
Entity Public Float	$2,588,759	'
Amendment Flag	'false	'
Entity Central Index Key	'0001136174	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'FY	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$1,136	$3,153
Receivables, net of allowance for doubtful accounts of $0 and $0, respectively	173	69
Receivables from related party	115	173
Prepaids and other current assets	275	227
Total current assets	1,699	3,622
Long-term assets	'	'
Property and equipment, net of accumulated depreciation of $2,001 and $4,668, respectively	366	59
Intangible assets, net of accumulated amortization of $401 and $892, respectively	118	1,048
Deposits and other assets	440	205
Total Assets	2,623	4,934
Current liabilities	'	'
Accounts payable	1,148	1,642
Accrued compensation and benefits	1,181	958
Deferred revenue	534	278
Other accrued liabilities	1,270	1,120
Total current liabilities	4,133	3,998
Long-term liabilities	'	'
Deferred rent and other long-term liabilities	160	18
Capital leases	26	18
Warrant liabilities	16,347	14,658
Total Liabilities	20,666	18,692
Stockholders' deficit	'	'
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized; 18,835,571 and 11,497,826 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	2	1
Additional paid-in-capital	209,169	208,776
Accumulated deficit	-227,214	-222,535
Total Stockholders' deficit	-18,043	-13,758
Total Liabilities and Stockholders' Deficit	$2,623	$4,934

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Allowance For Doubtful Accounts (in Dollars)	$0	$0
Property and equipment, accumulated depreciation (in Dollars)	2,001	4,668
Intangible assets, accumulated amortization (in Dollars)	$401	$892
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock,shares issued	18,835,571	11,497,826
Common stock, shares outstanding	18,835,571	11,497,826

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Revenues	'		'
Healthcare services revenues	$754,000		$375,000
License and management services revenues	112,000		166,000
Total revenues	866,000		541,000
Operating expenses	'		'
Cost of services	885,000		816,000
General and administrative	6,115,000		8,341,000
Impairment losses	795,000		656,000
Depreciation and amortization	170,000		289,000
Total operating expenses	7,965,000		10,102,000
Loss from operations	-7,099,000		-9,561,000
Interest and other income	106,000		'
Interest expense	-3,069,000		-4,811,000
Change in fair value of warrant liability	5,392,000		2,724,000
Loss before provision for income taxes	-4,670,000		-11,648,000
Provision for income taxes	9,000		-5,000
Net Loss	($4,679,000)		($11,643,000)
Basic and diluted net income (loss) per share:*	'		'
Net loss per share* (in Dollars per share)	($0.32)	[1]	($2.01)	[1]
Weighted number of shares outstanding* (in Shares)	14,604	[1]	5,780	[1]
[1]	The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)		Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Issuance 1 [Member]	Total
		Issuance 1 [Member]	USD ($)	Issuance 1 [Member]	USD ($)	USD ($)	USD ($)	USD ($)
				USD ($)
Balance at Dec. 31, 2011		'	$4,000	'	$206,392,000	($210,892,000)	'	($4,496,000)
Balance (in Shares) at Dec. 31, 2011	[1]	'	33,901,458	'	'	'	'	'
Common stock issued for outside services		'	'	73,000	'	'	73,000	'
Common stock issued for outside services (in Shares)	[1]	325,000	'	'	'	'	'	'
Common stock issued, net of expenses		'	8,000	'	409,000	'	'	417,000
Common stock issued, net of expenses (in Shares)		'	86,001,482	'	'	'	'	'
10:1 Reverse-stock split adjustment		'	-11,000	'	11,000	'	'	'
10:1 Reverse-stock split adjustment (in Shares)	[1]	'	-108,205,114	'	'	'	'	'
Share-based Compensation Expense		'	'	'	1,891,000	'	'	1,891,000
Net loss		'	'	'	'	-11,643,000	'	-11,643,000
Balance at Dec. 31, 2012		'	1,000	'	208,776,000	-222,535,000	'	-13,758,000
Balance (in Shares) at Dec. 31, 2012	[1]	'	12,022,826	'	'	'	'	'
Exercise of Warrants		'	1,000	'	180,000	'	'	181,000
Exercise of Warrants (in Shares)	[1]	'	69,886	'	'	'	'	'
Common stock issued, net of expenses		'	'	'	'	'	'	0
Common stock issued, net of expenses (in Shares)		'	6,742,859	'	'	'	'	'
Share-based Compensation Expense		'	'	'	213,000	'	'	213,000
Net loss		'	'	'	'	-4,679,000	'	-4,679,000
Balance at Dec. 31, 2013		'	$2,000	'	$209,169,000	($227,214,000)	'	($18,043,000)
Balance (in Shares) at Dec. 31, 2013	[1]	'	18,835,571	'	'	'	'	'
[1]	The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating activities:	'	'
Net loss	($4,679,000)	($11,643,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	170,000	289,000
Amortization of debt discount and issuance costs included in interest expense	3,066,000	4,793,000
Provision for doubtful accounts	9,000	-4,000
Deferred rent	-22,000	'
Share-based compensation expense	214,000	2,190,000
Fair value adjustment on warrant liability	-5,392,000	-2,724,000
Impairment losses	795,000	656,000
(Gain) or loss on disposition of assets	'	-1,000
Changes in current assets and liabilities:	'	'
Receivables	-242,000	-58,000
Prepaids and other current assets	-19,000	-105,000
Deferred revenue	256,000	219,000
Accounts payable and other accrued liabilities	-90,000	237,000
Net cash used in operating activities	-5,935,000	-6,151,000
Investing activities:	'	'
Purchases of property and equipment	'	-11,000
Deposits and other assets	-265,000	-5,000
Net cash used in investing activities	-265,000	-16,000
Financing activities:	'	'
Proceeds from the issuance of common stock and warrants	4,174,000	7,586,000
Proceeds from the exercise of warrants	23,000	'
Proceeds from financing notes	'	975,000
Capital lease obligations	-14,000	-12,000
Net cash provided by financing activities	4,183,000	8,549,000
Net increase (decrease) in cash and cash equivalents	-2,017,000	2,382,000
Cash and cash equivalents at beginning of period	3,153,000	771,000
Cash and cash equivalents at end of period	1,136,000	3,153,000
Supplemental disclosure of cash paid	'	'
Income taxes	40,000	107,000
Supplemental disclosure of non-cash activity	'	'
Beneficial conversion feature related to financing	'	253,000
Property and equipment acquired through capital leases and other financing	33,000	33,000
Outside Services [Member]	'	'
Supplemental disclosure of non-cash activity	'	'
Common stock issued	'	73,000
Conversion Of Debt [Member]	'	'
Supplemental disclosure of non-cash activity	'	'
Common stock issued	'	975,000
Services [Member]	'	'
Supplemental disclosure of non-cash activity	'	'
Common stock issued	'	387,000
Exercise Of Warrants [Member]	'	'
Supplemental disclosure of non-cash activity	'	'
Common stock issued	$156,000	'

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 1.  Summary of Significant Accounting Policies
	Description of Business
	We are a healthcare services company, providing specialized health services designed to assist health plans and other third party payors to manage and treat their high cost substance dependence members through a network of healthcare providers and our employees. The OnTrak substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term “care coaching.” We have a company managed psychiatry practice that offers a variety of mental health and substance dependence treatments primarily on a fee-for-service basis.
	We manage and report our operations through two business segments: healthcare services and license and management services. The healthcare services segment includes OnTrak and its integrated substance dependence solutions marketed to health plans and other third party payors through a network of licensed and company managed healthcare providers. The license and management segment primarily represents our managed treatment office which offers a range of addiction treatment and mental health services.
	Basis of Consolidation and Presentation and Going Concern
	Our consolidated financial statements include the accounts of the company, our wholly-owned subsidiaries, and a managed professional medical corporation. Based on the provisions of the management service agreement between us and a medical corporation, we have determined that the medical corporation is a variable interest entity (VIE), and that we are the primary beneficiary as defined in the Financial Accounting Standards Board (FASB) rules for accounting for variable interest entities. Accordingly, we are required to consolidate the revenues and expenses of the managed medical corporation.
	Our financial statements have been prepared on the basis that we will continue as a going concern. At December 31, 2013, cash and cash equivalents amounted to $1.1 million and we had a working capital deficit of approximately $2.4 million. We have incurred significant operating losses and negative cash flows from operations since our inception. During the year ended December 31, 2013, our cash used in operating activities amounted $5.9 million. We anticipate continuing to incur negative cash flows and net losses for the next twelve months. The financial statements do not include any adjustments relating to the recoverability of the carrying amount of the recorded assets or the amount of liabilities that might result from the outcome of this uncertainty. As of December 31, 2013, these conditions raised substantial doubt as to our ability to continue as a going concern.
	Our ability to fund our ongoing operations and continue as a going concern is dependent on signing and generating fees from existing and new contracts for our Catasys managed care programs and the success of management’s plans to increase revenue and continue to control expenses. We are operating programs in Kansas, Massachusetts, Oklahoma, Louisiana, Kentucky, West Virginia, and Wisconsin. The programs in Kentucky and West Virginia commenced enrollment in the fourth quarter of 2013 and the Wisconsin program, which represents our first managed care Medicaid health plan customer, commenced enrollment in the first quarter of 2014. In March 2013, we signed an agreement with a national health plan to provide services to their members in New Jersey, which we expect to commence enrollment in the second quarter of 2014. We have generated fees from the launched programs and expect to increase enrollment and fees throughout 2014. However, there can be no assurance that we will generate such fees. In addition, we continue to seek ways to streamline our operating expenses.
	We and our Chief Executive Officer are party to a litigation in which the plaintiffs assert causes of action for conversion, a request for an order to set aside fraudulent conveyance and breach of contract. While the trial and appellate courts have ruled in our favor the plaintiff has filed a request to appeal to the state of Supreme Court. While we believe the plaintiffs’ claims are without merit and we intend to continue to vigorously defend the case, there can be no assurance that the litigation will ultimately be resolved in our favor. If this case is decided against us or our Chief Executive Officer, it may cause us to pay substantial damages, and other related fees. Regardless of whether this litigation is resolved in our favor, any lawsuit to which we are a party will likely be expensive and time consuming to defend or resolve. Costs of defense and any damages resulting from litigation, a ruling against us or a settlement of the litigation could have a significant negative impact our liquidity, including our cash flows.
	All inter-company transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts in the financial statements and disclosed in the accompanying notes. Significant areas requiring the use of management estimates include expense accruals, accounts receivable allowances, accrued claims payable, the useful life of depreciable and amortizable assets, the evaluation of asset impairment, the valuation of warrant liabilities, and shared-based compensation. Actual results could differ from those estimates.
	Revenue Recognition
	Healthcare Services
	Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis based on enrolled members. To the extent our contracts may include a minimum performance guarantee, we reserve a portion of the monthly fees that may be at risk until the performance measurement period is completed. To the extent we receive case rates that are not subject to performance guarantees we recognize the case rate ratably over twelve months.
	License and Management Services
	Our license and management services revenues are derived from our managed treatment center, which we include in our consolidated financial statements, and which are derived from charging fees directly to patients for treatment and are recorded when services are provided. Revenues from patients treated with our proprietary treatment program are recorded based on the number of days of treatment completed during the period as a percentage of the total number treatment days for the treatment program. Revenues from other services are recognized when services are rendered.
	Cost of Services
	Healthcare Services
	Cost of healthcare services consists primarily of salaries related to our care coaches, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Healthcare services cost of services is recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOnTrakTM database within the contracted timeframe, with all required billing elements correctly completed by the service provider.
	License and Management Services
	Cost of license and management services primarily represents direct costs associated with providing care to patients that are incurred in connection with our managed treatment center. Costs are recognized in the periods in which medical treatment is provided. Such costs include, but are not limited to, direct labor costs, medical supplies, and medications.
	Share-Based Compensation
	Our 2010 Stock Incentive Plan, as amended (“the Plan”), provides for the issuance of up to 1,825,000 shares of our common stock. Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than ten years from the date of grant and employee and board of director awards generally vest over three to five years. At December 31, 2013, we had an aggregate of 482,177 vested and unvested shares outstanding and 1,285,586 shares available for future awards.
	Total share-based compensation expense on a consolidated basis amounted to $213,000 and $2.2 million for the years ended December 31, 2013 and 2012, respectively.
	Stock Options – Employees and Directors
	We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.
	There were no new stock options granted during 2013. The estimated weighted average fair values of options granted during 2012 was $3.30 per share, and were calculated using the Black-Scholes pricing model based on the following assumptions:
		2012
	Expected volatility		151	%
	Risk-free interest rate		1.02	%
	Weighted average expected lives in years		6
	Expected dividend		0	%
	The expected volatility assumption for 2012 was based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected lives in years for 2012 reflect the application of the simplified method set out in Security and Exchange Commission (SEC) Staff Accounting Bulletin (SAB) 107 (and as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. We use historical data to estimate the rate of forfeitures assumption for awards granted to employees.
	We have elected to adopt the detailed method prescribed in FASB’s accounting rules for share-based compensation expense for calculating the beginning balance of the additional paid-in capital pool (APIC pool) related to the tax effects of employee share-based compensation, and to determine the subsequent impact on the APIC pool and consolidated statements of cash flows of the tax effects of employee share-based compensation awards that were outstanding upon adoption of such rules on January 1, 2006.
	Stock Options and Warrants – Non-employees
	We account for the issuance of stock options and warrants for services from non-employees by estimating the fair value of stock options and warrants issued using the Black-Scholes pricing model. This model’s calculations incorporate the exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, expected life of the option or warrant, expected volatility of our stock and expected dividends.
	For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.
	From time to time, we have retained terminated employees as part-time consultants upon their resignation from the company. Because the employees continue to provide services to us, their options continue to vest in accordance with the original terms. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards under FASB’s accounting rules for share-based expense but are instead accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. We recorded no expense during 2013 and 2012, respectively, associated with modified liability awards.
	Income Taxes
	We account for income taxes using the liability method in accordance with Accounting Standards Committee (“ASC”) 740 “Income Taxes” (formerly SFAS 109, “Accounting for Income Taxes”). To date, no current income tax liability has been recorded due to our accumulated net losses. Deferred tax assets and liabilities are recognized for temporary differences between the financial statement carrying amounts of assets and liabilities and the amounts that are reported in the tax returns. Deferred tax assets and liabilities are recorded on a net basis; however, our net deferred tax assets have been fully reserved by a valuation allowance due to the uncertainty of our ability to realize future taxable income and to recover our net deferred tax assets.
	In June 2006, the FASB issued FASB Interpretation No. 48 (FIN 48), “Accounting for Uncertainty in Income Taxes” (incorporated into ASC 740), which clarifies the accounting for uncertainty in income taxes. FIN 48 requires that companies recognize in the consolidated financial statements the impact of a tax position if that position is more likely than not of being sustained on audit based on the technical merits of the position. FIN 48 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. We adopted FIN 48 on January 1, 2007, with no impact to our consolidated financial statements.
	Basic and Diluted Loss per Share
	Basic loss per share is computed by dividing the net loss to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Basic and diluted loss per share has been adjusted retroactively for the 10-for-1 reverse stock split that occurred on May 6, 2013.
	Common equivalent shares, consisting of approximately 18,342,335 and 11,730,069 of incremental common shares as of December 31, 2013 and 2012, respectively, issuable upon the exercise of stock options and warrants, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.
	Cash and Cash Equivalents
	We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
	Marketable Securities
	Investments include certificates of deposits with maturity dates greater than three months when purchased. These investments are classified as deposits, are reflected in long terms assets as part of deposits and other assets and are stated at fair market value.
	Our marketable securities consisted of investments with the following maturities as of December 31, 2013 and 2012:
	(in thousands)	Fair Market Value			Less than 1 Year		More than 10 Years
	Balance at December 31, 2012
	Certificates of deposit	$	175		$	175	$	-
	Balance at December 31, 2013
	Certificates of deposit	$	175		$	175	$	-
	The carrying value of all securities presented above approximated fair market value at December 31, 2013 and 2012, respectively.
	Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:
	Level Input:	Input Definition:
	Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
	Level II	Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
	Level III	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
	The following tables summarize fair value measurements by level at December 31, 2013 and 2012, respectively, for assets and liabilities measured at fair value on a recurring basis:
		Balance at December 31, 2012
(Amounts in thousands)	Level I			Level II			Level III		Total
Certificates of deposit		175			-			-		175
Total assets		175			-			-		175
Warrant liabilities		-			-			14,658		14,658
Total liabilities		-			-			14,658		14,658
		Balance at December 31, 2013
(Amounts in thousands)	Level I			Level II			Level III		Total
Certificates of deposit		175			-			-		175
Total assets		175			-			-		175
Warrant liabilities		-			-			16,347		16,347
Total liabilities		-			-			16,347		16,347
We measure warrant liabilities issued from our debt and equity financings on a recurring basis. In accordance with current accounting rules, the warrant liabilities are being marked-to-market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes option pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. Significant increases (decreases) in any of these inputs could result in significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the expected term is accompanied by a change in the assumption used for the risk free rate and the expected stock. See Warrant Liabilities below.
The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the years ended December 31, 2013 and 2012:
(Dollars in thousands)	Level III Warrant Liabilities
Balance as of December 31, 2011	$	4,528
Change in fair value		(2,724	)
Issuance of Warrants		12,854
Balance as of December 31, 2012	$	14,658
Reclassification to equity		(156	)
Change in fair value		(5,392	)
Issuance of Warrants		7,237
Balance as of December 31, 2013	$	16,347
Fair Value Information about Financial Instruments Not Measured at Fair Value
FASB rules regarding fair value disclosures of financial instruments requires disclosure of fair value information about certain financial instruments for which it is practical to estimate that value.  The carrying amounts reported in our consolidated balance sheets for cash, cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments. There was no outstanding debt for the years ending December 31, 2013 and 2012, respectively. Considerable judgment is required to develop estimates of fair value.  Accordingly, the estimates are not necessarily indicative of the amounts we could realize in a current market exchange.  The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.
Intangible Assets
Intellectual Property
Intellectual property consists primarily of the costs associated with acquiring certain technology, patents, patents pending, know-how and related intangible assets with respect to programs for treatment of dependence to alcohol, cocaine, methamphetamines other addictive stimulants, and anxiety. These long-term assets are stated at cost and are being amortized on a straight-line basis over the life of the respective patents, or patent applications, which is approximately seven years at December 31, 2013.
Impairment of Long-Lived Assets
Long-lived assets such as property, equipment and intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In reviewing for impairment, we compare the carrying value of such assets to the estimated undiscounted future cash flows expected from the use of the assets and their eventual disposition. When the estimated undiscounted future cash flows are less than their carrying amount, an impairment loss is recognized equal to the difference between the assets’ fair value and their carrying value.
We performed an impairment analysis on intellectual property at December 31, 2013. For certain intangible assets, we considered numerous factors and we determined that the carrying value was not recoverable, and exceeded the fair-value. We recorded an impairment charge of $795,000 for these assets at December 31, 2013. We determined that the estimated lives of the remaining intellectual property properly reflected the current remaining economic lives of the assets.
We performed an impairment analysis on intellectual property at December 31, 2012. For certain intangible assets, we considered numerous factors and we determined that the carrying value was not recoverable, and exceeded the fair-value. We recorded an impairment charge of $656,000 for these assets at December 31, 2012. We determined that the estimated lives of the remaining intellectual property properly reflected the current remaining economic lives of the assets.
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years. Construction in progress is not depreciated until the related asset is placed into service.
Capital Leases
Assets held under capital leases include computer equipment, and are recorded at the lower of the net present value of the minimum lease payments or the fair value of the leased asset at the inception of the lease. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. All lease agreements meet at least one of the four requirements of a capital lease in accordance with ASC 840 of the codification.
Variable Interest Entities
Generally, an entity is defined as a variable interest entity (VIE) under current accounting rules if it has (a) equity that is insufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (b) equity investors that cannot make significant decisions about the entity’s operations, or that do not absorb the expected losses or receive the expected returns of the entity. When determining whether an entity that is a business qualifies as a VIE, we also consider whether (i) we participated significantly in the design of the entity, (ii) we provided more than half of the total financial support to the entity, and (iii) substantially all of the activities of the VIE either involve us or are conducted on our behalf. A VIE is consolidated by its primary beneficiary, which is the party that absorbs or receives a majority of the entity’s expected losses or expected residual returns.
As discussed under the heading Management Services Agreement below, we have an MSA with a managed medical corporation. Under this MSA, the equity owner of the affiliated medical group has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We participate significantly in the design of this MSA. We also agree to provide working capital loans to allow for the medical group to pay for its obligations. Substantially all of the activities of this managed medical corporation either involve us or are conducted for our benefit, as evidenced by the fact that under the MSA, we agree to provide and perform all non-medical management and administrative services for the medical group. Payment of our management fee is subordinate to payments of the obligations of the medical group, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated medical group or other third party. Creditors of the managed medical corporation do not have recourse to our general credit.
Based on the design and provisions of this MSA and the working capital loan provided to the medical group, we have determined that the managed medical corporation is a VIE, and that we are the primary beneficiary as defined in current accounting rules. Accordingly, we are required to consolidate the revenues and expenses of such managed medical corporation.
Warrant Liabilities
In April 2013, we entered into the securities purchase agreements with several investors, including Crede CG III, Ltd. (“Crede III”), an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and Shamus, LLC (“Shamus”) an affiliate of the Company, relating to the sale and issuance of an aggregate of 2,192,857 shares of common stock and warrants (the “April Warrants”) to purchase an aggregate of 2,192,857 shares of common stock at an exercise price of $0.70 per share for aggregate gross proceeds of approximately $1.5 million (the “April Offering”). The April Offering provides that in the event that we effectuate a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue the Adjustment Shares. We effectuated a reverse split on May 6, 2013, and no Adjustment Shares were issued.
The April Warrants expire in April 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the April Warrants, the exercise price of the April Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the April Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period. In October 2013, we completed a private placement at $0.58 per share and the warrant shares associated with the April Offering were reduced to $0.58 per share.
In October 2013, we entered into the securities and purchase agreements with several investors including Crede III and Shamus, relating to the sale and issuance of an aggregate of 4,550,002 shares of common stock and warrants (the “October Warrants”) to purchase an aggregate of 4,550,002 shares of common stock at an exercise price of $0.58 per share for aggregate gross proceeds of approximately $2.6 million (the “October Offering”). The October Offering provides that in the event that we effectuate a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue the Adjustment Shares.
The October Warrants expire in October 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the October Warrants, the exercise price of the October Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the October Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
In April 2012, we entered into security purchase agreements with several investors, including Crede III and David Smith, relating to the sale and issuance of an aggregate of 2,144,005shares of common stock and warrants (the “April 2012 Warrants”) to purchase an aggregate of 2,144,005 shares of common stock at an exercise price of $1.60 per share for aggregate gross proceeds of approximately $3,430,000 (the “April 2012 Offering”). The April 2012 Offering provide that in the event that the Company effectuates a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue the Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
The April 2012 Warrants expire in April 2017, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the April 2012 Warrants, the exercise price of the April 2012 Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the April 2012 Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
In May 2012, we entered into a securities purchase agreement with an accredited investor, on the same terms of the April 2012 Offering disclosed above, relating to the sale and issuance of 25,000 shares of common stock and warrants to purchase an aggregate of 25,000 shares of common stock at an exercise price of $1.60 per share, for gross proceeds of $40,000.
In May 2012, we issued warrants to purchase an aggregate of 12,000 shares of common stock at an exercise price of $1.60 per share, associated with financing costs.
In June 2012, we issued 6,250 restricted shares of common stock to a consultant for investor relation services to be performed beginning June 2012 and ending November 2012.
In September 2012, we entered into securities purchase agreements with several investors including Crede III and David Smith, relating to the sale and issuance of an aggregate of 1,719,000 shares of the Company’s common stock and warrants (the “September Warrants”) to purchase an aggregate of 1,719,000 shares of common stock, at an exercise price of $1.00 per share, for aggregate gross proceeds of approximately $1.7 million (the “September Offering”). The foregoing issuances triggered anti-dilution provisions in certain of the Company’s outstanding warrants. As a result, the exercise price of these warrants decreased to $1.00 per share, however, the number of shares issuable under these warrants remained unchanged. The September Offering provide that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the September Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
The September Warrants expire in September 2017, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the September Warrants, the exercise price of the September Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the September Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
In December 2012, we entered into securities purchase agreements with several investors including Crede III and David Smith, relating to the sale and issuance of an aggregate of 4,712,143 shares of the Company’s common stock and warrants (the “December Warrants”) to purchase an aggregate of 4,712,143 shares of common stock, at an exercise price of $0.70 per share, for aggregate gross proceeds of approximately $3.3 million (the “December Offering”). The foregoing issuances triggered anti-dilution provisions in certain of the Company’s outstanding warrants. As a result, the exercise price of these warrants decreased to $0.70 per share, however, the number of shares issuable under these warrants remained unchanged. The December Offering provide that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the December Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
The December Warrants expire in December 2017, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the September Warrants, the exercise price of the September Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the December Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
We have issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, October 2013, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.
For the years ended December 31, 2013 and 2012, we recognized a gain of $5.4 million and $2.7 million, respectively, related to the revaluation of our warrant liabilities.
Concentration of Credit Risk
Financial instruments, which potentially subject us to a concentration of risk, include cash and accounts receivable. All of our customers are based in the United States at this time and we are not subject to exchange risk for accounts receivable.
The Company maintains its cash in domestic financial institutions subject to insurance coverage issued by the Federal Deposit Insurance Corporation (FDIC). Under FDIC rules, the company is entitled to aggregate coverage as defined by the Federal regulation per account type per separate legal entity per financial institution. The Company has incurred no losses as a result of any credit risk exposures.
For the year ended December 31, 2013, two customers accounted for approximately 76% of revenues and four customers accounted for approximately 91% of accounts receivable.
Recently Issued or Newly Adopted Accounting Pronouncements
In December 2011, the FASB issued Accounting Standards Update (“ASU”) No. 2011-11, Disclosures about Offsetting Assets and Liabilities (“ASU 2011-11”). The amendments in this update require enhanced disclosures around financial instruments and derivative instruments that are either (1) offset in accordance with either ASC 210-20-45 or ASC 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either ASC 210-20-45 or ASC 815-10-45. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The amendments are effective during interim and annual periods beginning after December 31, 2012. The adoption of ASU No. 2011-11 did not have a material effect on our consolidated financial statements or disclosures.
In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-02”). ASU 2013-02 amends ASC 220, Comprehensive Income (“ASC 220”), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.
In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, (“ASU 2013-02”), which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. The adoption of ASU 2013-11 did not have a material effect on our consolidated financial position or results of operations.

Note_2_Management_Services_Agr

Note 2 - Management Services Agreements	12 Months Ended
	Dec. 31, 2013
Management Services Agreements [Abstract]	'
Management Services Agreements [Text Block]	'
	Note 2.  Management Services Agreement
	We have an executed MSA with a medical professional corporation and related treatment center. Under the MSA, we license to the treatment center the right to use our proprietary treatment programs and related trademarks and provide all required day-to-day business management services, including, but not limited to:
		●	general administrative support services;
		●	information systems;
		●	recordkeeping;
		●	scheduling;
		●	billing and collection;
		●	marketing and local business development; and
		●	obtaining and maintaining all federal, state and local licenses, certifications and regulatory permits.
	The treatment center retains the sole right and obligation to provide medical services to its patients and to make other medically related decisions, such as the choice of medical professionals to hire or medical equipment to acquire and the ordering of drugs.
	In addition, we provide office space to the treatment center on a non-exclusive basis, and we are responsible for all costs associated with rent and utilities. The treatment center pays us a monthly fee equal to the aggregate amount of (a) our costs of providing management services (including reasonable overhead allocable to the delivery of our services and including salaries, rent, equipment, and tenant improvements incurred for the benefit of the medical group, provided that any capitalized costs will be amortized over a five year period), (b) 10%-15% of the foregoing costs, and (c) any performance bonus amount, as determined by the treatment center at its sole discretion. The treatment center’s payment of our fee is subordinate to payment of the treatment center's obligations, including physician fees and medical group employee compensation.
	We have also agreed to provide a credit facility to the treatment center to be available as a working capital loan, with interest at the Prime Rate plus 2%.  Funds are advanced pursuant to the terms of the MSA described above. The notes are due on demand or upon termination of the MSA. At December 31, 2013 and 2012, there was one outstanding credit facility under which $13.1 million and $12.3 million was outstanding, respectively. Our maximum exposure to loss could exceed this amount, and cannot be quantified as it is contingent upon the amount of losses incurred by the treatment center that we are required to fund under the credit facility.
	Under the MSA, the equity owner of the affiliated treatment center has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We also agree to provide a working capital loan to allow for the treatment center to pay for its obligations. Substantially all of the activities of these managed medical corporations either involve us or are conducted for our benefit, as evidenced by the facts that (i) the operations of the managed medical corporation is conducted primarily using our licensed protocols and (ii) under the MSA, we agree to provide and perform all non-medical management and administrative services for the treatment center. Payment of our management fee is subordinate to payments of the obligations of the treatment center, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated treatment center or other third party. Creditors of the managed medical corporation do not have recourse to our general credit. Based on these facts, we have determined that the managed medical corporation is a VIE and that we are the primary beneficiary as defined in current accounting rules.  Accordingly, we are required to consolidate the assets, liabilities, revenues and expenses of the managed treatment center.
	The amounts and classification of assets and liabilities of the VIE included in our consolidated balance sheets as of December 31, 2013 and 2012 are as follows:
	(in thousands)		31-Dec-13		December 31, 2012
	Cash and cash equivalents		$	24	$	11
	Receivables, net			24		19
	Total assets		$	48		30
	Accounts payable			25		15
	Note payable to Catasys, Inc.			13,119		12,267
	Total liabilities		$	13,144		12,282

Note_3_Accounts_Receivable

Note 3 - Accounts Receivable	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	'
	Note 3.  Accounts Receivable
	Accounts receivables consisted of the following as of December 31, 2013 and 2012:
		December 31,
	(in thousands)	2013		2012
	Healthcare fees	$	146	$	50
	Patient fees receivable		24		19
	Other		3		-
	Total receivables	$	173	$	69
	Less allowance for doubtful accounts		-		-
	Total receivables, net	$	173	$	69
	We use the specific identification method for recording the provision for doubtful accounts, which was $0 and $0 as of December 31, 2013 and 2012, respectively. Accounts written off against the allowance for doubtful accounts totaled $9,000 and $0 for the years ended December 31, 2013 and 2012, respectively.

Note_4_Receivable_Related_Part

Note 4 - Receivable - Related Party	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 4.  Receivable – Related Party
	In December 2010, we entered into a three-year sublease agreement with Xoftek, Inc., an affiliate of our Chairman and CEO, to sublease approximately one-third of our office space for a three-year term for a month rent of approximately $11,000 per month. We offset a $186,000 payable due to our Chairman and Chief Executive Officer against this receivable at December 31, 2013. The related party receivable as of December 31, 2013 and 2012 was $115,000 and $173,000, respectively. We have received approximately $267,000 in payments as of December 31, 2013.

Note_5_Property_and_Equipment

Note 5 - Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 5.  Property and Equipment
	Property and equipment consisted of the following as of December 31, 2013 and 2012:
	(in thousands)	2013			2012
	Furniture and equipment	$	2,054		$	3,169
	Leasehold improvements		313			1,558
	Total property and equipment		2,367			4,727
	Less accumulated depreciation and amortization		(2,001	)		(4,668	)
	Total property and equipment, net	$	366		$	59
	Depreciation expense was $35,000 and $73,000 for the years ended December 31, 2013 and 2012, respectively.
	At December 31, 2013, we wrote off $2.7 million of the fully depreciated balance of leasehold improvements, furniture, and equipment related to the premises we vacated in 2013.

Note_6_Intangible_Assets

Note 6 - Intangible Assets	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 6.  Intangible Assets
	Intellectual property consists primarily of the costs associated with acquiring certain technology, patents, patents pending, know-how and related intangible assets with respect to programs for treatment of dependence to alcohol, cocaine, methamphetamine, other addictive stimulants, and anxiety. Intellectual property is being amortized on a straight-line basis from the date costs are incurred over the remaining life of the respective patents or patent applications, which is approximately seven years at December 31, 2013. As of December 31, 2013 and 2012, intangible assets were as follows:
	(in thousands)	2013			2012
	Intellectual property	$	519		$	1,940
	Less accumulated amortization		(401	)		(892	)
	Total intangibles, net	$	118		$	1,048
	Amortization expense for all intangible assets amounted to $135,000 and $213,000 for the years ended December 31, 2013 and 2012, respectively. Estimated amortization expense for intellectual property for the next five years ending December 31, is approximately $80,000. We recorded impairment losses of $795,000 and $656,000 for the years ended December 31, 2013 and 2012, respectively.

Note_7_Capital_Lease_Obligatio

Note 7 - Capital Lease Obligations	12 Months Ended
	Dec. 31, 2013
Leases, Capital [Abstract]	'
Capital Leases in Financial Statements of Lessee Disclosure [Text Block]	'
	Note 7.  Capital Lease Obligations
	We lease certain computer equipment under agreements entered into during 2013 that are classified as capital leases. The computer equipment under capital leases is included in furniture and equipment on our condensed consolidated balance sheets was $64,000 and $31,000 at December 31, 2013 and 2012, respectively. Accumulated depreciation of the leased equipment at December 31, 2013 and 2012, was approximately $18,000 and $4,000, respectively.
	The future minimum lease payments required under the capital leases and the present values of the net minimum lease payments, as of December 31, 2013, are as follows:
	(in thousands)	Amount
	Year ending December 31,
	2014	$	20
	2015		35
	2016		5
	Total minimum lease payments		60
	Less amounts representing interest		(9	)
	Capital lease obligations, net of interest		51
	Less current maturities of capital lease obligations		(25	)
	Long-term capital lease obligations	$	26

Note_8_Income_Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 8.  Income Taxes
	As of December 31, 2013, the Company had net federal operating loss carry forwards and state operating loss carry forwards of approximately $172 million and $169 million, respectively. The net federal operating loss carry forwards begin to expire in 2023, and net state operating loss carry forwards begin to expire in 2013. The majority of the foreign net operating loss carry forwards expire over the next seven years.
	The primary components of temporary differences which give rise to our net deferred tax assets are as follows:
		2013			2012
	(in thousands)
	Federal, state and foreign net operating losses	$	68,199		$	66,120
	Stock based compensation		8,228			7,943
	Accrued liabilities		430			344
	Other temporary differences		(2,595	)		(2,668	)
	Valuation allowance		(74,262	)		(71,739	)
		$	-		$	-
	The Company has provided a valuation allowance in full on its net deferred tax assets in accordance with ASC 740 Income Taxes (formerly SFAS No. 109, "Accounting for Income Taxes"). Because of the Company's continued losses, management assessed the realizability of its net deferred tax assets as being less than the more-likely-than-not criteria set forth by ASC 740. Furthermore, certain portions of the Company's net operating loss carryforwards were acquired, and therefore subject to further limitation set forth under the federal tax code, which could further limit the Company's ability to realize its deferred tax assets.
	A reconciliation between the statutory federal income tax rate and the effective income tax rate for the years ended December 31, is as follows
		2013			2012
	Federal statutory rate		-34	%		-34	%
	State taxes, net of federal benefit		-37.1	%		2.8	%
	Non-deductible goodwill		0	%		0	%
	ISO / ESPP		1.3	%		4.5	%
	Other		0.4	%		-0.9	%
	Change in valuation allowance		69.6	%		27.6	%
	Tax provision		0.2	%		0	%
	Current accounting rules require that companies recognize in the consolidated financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. We file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. Tax years that remain subject to examinations by tax authorities are 2008 through 2011. The federal and material foreign jurisdictions statutes of limitations began to expire in 2008. There are no current income tax audits in any jurisdictions for open tax years and, as of December 31, 2013, there have been no material changes to our tax positions.
	The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest and penalties for the years ended December 31, 2013 and 2012, respectively. The Company files income tax returns with the Internal Revenue Service (“IRS”) and the state of California. For jurisdictions in which tax filings are prepared, the Company is no longer subject to income tax examinations by state tax authorities for tax years through 2007, and by the IRS for tax years through 2008. The Company’s net operating loss carryforwards are subject to IRS examination until they are fully utilized and such tax years are closed.

Note_9_Equity_Financings

Note 9 - Equity Financings	12 Months Ended
	Dec. 31, 2013
Equity Financing [Abstract]	'
Equity Financing [Text Block]	'
	Note 9.  Equity Financings
	In April 2013, we entered into securities purchase agreements with several investors, including Crede CG III and Shamus, relating to the sale and issuance of an aggregate of 2,192,857 shares of common stock, and warrants (the “April Warrants”) to purchase an aggregate of 2,192,857 shares of Common Stock at an exercise price of $0.70 per share for aggregate gross proceeds of approximately $1,535,000 (the “April Offering”).    The April Offering provide that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the April Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends. We effectuated a reverse split on May 6, 2013, and no Adjustment Shares were issued.
	In October 2013, we entered into securities purchase agreements with several investors, including Crede CG III and Shamus, relating to the sale and issuance of an aggregate of 4,550,002 shares of common stock, and warrants (the “October Warrants”) to purchase an aggregate of 4,550,002 shares of Common Stock at an exercise price of $0.58 per share for aggregate gross proceeds of approximately $2.6 million. The foregoing issuances triggered anti-dilution provisions in certain of the Company’s outstanding warrants. As a result, the exercise price of these warrants decreased to $0.58 per share, however, the number of shares issuable under these warrants remained unchanged. The October Offering provides that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the October Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
	In April 2012, we entered into security purchase agreements with several investors, including Crede III and David Smith, relating to the sale and issuance of an aggregate of 2,144,005 shares of common stock and warrants (the “April 2012 Warrants”) to purchase an aggregate of 2,144,005 shares of common stock at an exercise price of $1.60 per share for aggregate gross proceeds of approximately $3,430,000 (the “April 2012 Offering”). The April 2012 Offering provide that in the event that the Company effectuates a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue the Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
	In May 2012, we entered into a securities purchase agreement with an accredited investor, on the same terms of the April 2012 Offering disclosed above, relating to the sale and issuance of 25,000 shares of common stock and warrants to purchase an aggregate of 25,000 shares of common stock at an exercise price of $1.60 per share for gross proceeds of $40,000.
	In September 2012, we entered into securities purchase agreements with several investors including Crede III and David Smith, relating to the sale and issuance of an aggregate of 1,719,000 shares of the Company’s common stock and warrants (the “September Warrants”) to purchase an aggregate of 1,719,000 shares of common stock, at an exercise price of $1.00 per share, for aggregate gross proceeds of approximately $1.7 million (the “September Offering”). The foregoing issuances triggered anti-dilution provisions in certain of the Company’s outstanding warrants. As a result, the exercise price of these warrants decreased to $1.00 per share, however, the number of shares issuable under these warrants remained unchanged. The September Agreements provide that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the September Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
	In December 2012, we entered into securities purchase agreements with several investors including Crede III and David Smith, relating to the sale and issuance of an aggregate of 4,712,143 shares of the Company’s common stock and warrants (the “December Warrants”) to purchase an aggregate of 4,712,142 shares of common stock, at an exercise price of $0.70 per share, for aggregate gross proceeds of approximately $3.3 million (the “December Offering”). The foregoing issuances triggered anti-dilution provisions in certain of the Company’s outstanding warrants. As a result, the exercise price of these warrants decreased to $0.70 per share, however, the number of shares issuable under these warrants remained unchanged. The December Agreements provide that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the December Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.

Note_10_Sharebased_Compensatio

Note 10 - Share-based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 10.  Share-based Compensation
	The Plan provides for the issuance of up to 1,825,000 shares of our common stock. Incentive stock options, under Section 422A of the Internal Revenue Code, non-qualified options, stock appreciation rights, limited stock appreciation rights and restricted stock grants are authorized under the Plan. We grant all such share-based compensation awards at no less than the fair market value of our stock on the date of grant, and have granted stock and stock options to executive officers, employees, members of our Board of Directors and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants; however, option rights expire no later than ten years from the date of grant and employee and Board of Director awards generally vest over three to five years on a straight-line basis. At December 31, 2013, we had 482,177 vested and unvested stock options outstanding and 1,285,586 shares reserved for future awards. Total share-based compensation expense amounted to $214,000 and $2.2 million for the years ended December 31, 2013 and 2012, respectively.
	Stock Options – Employees and Directors
	There were no stock options granted to employees and directors during 2013. During 2012, we granted options to employees and directors for 8,000 shares, at the weighted average per share exercise prices of $3.30, the fair market value of our common stock on the dates of grants. The estimated fair value of options granted to employees and directors during 2012 was $24,294, calculated using the Black-Scholes pricing model with the assumptions described in Note 1 – Summary of Significant Accounting Policies, Share-based Compensation.
	Stock option activity for employee and director grants is summarized as follows:
			Shares			Weighted Avg. Exercise Price
	Balance, December 31, 2011			481,000		$	47.5
	2012
	Granted			8,000			3.3
	Cancelled/Expired			(3,000	)		46.2
	Balance, December 31, 2012			486,000		$	47.2
	2013
	Granted			-			-
	Cancelled/Expired			(25,000	)		151.7
	Balance, December 31, 2013			461,000		$	19.69
	The weighted average remaining contractual life and weighted average exercise price of options outstanding as of December 31, 2013 were as follows:
								Options Outstanding						Options Exercisable
		Range of Exercise Prices						Shares		Weighted Average Remaining Life (yrs)		Weighted Average Price		Shares		Weighted Average Price
		$0.00		to	$20.00				448,000		7.15	$	15.67		439,000	$	15.91
		$20.01		to	$1,000.00				13,000		4.83		154.03		13,000		154.03
									461,000		7.08	$	19.57		452,000	$	19.88
	At December 31, 2013 and 2012, the number of options exercisable was 451,639 and 453,500, respectively, at weighted-average exercise prices of $20.00 and $47.20, respectively.
	Share-based compensation expense relating to stock options granted to employees and directors was $189,000 and $1.8 million for the years ended December 31, 2013 and 2012, respectively.
	As of December 31, 2013, there was $44,000 of unrecognized compensation costs related to non-vested share-based compensation arrangements granted to employees and directors under the Plans. These costs are expected to be recognized over a weighted-average period of 1.05 years.
	Stock Options and Warrants – Non-employees
	In addition to stock options granted under the Plan, we have also granted options and warrants to purchase our common stock to certain non-employees that have been approved by our Board of Directors. We granted options and warrants of 0 and 80,600 during 2013 and 2012, respectively.
	Stock option and warrant activity for non-employee grants for services is summarized as follows:
			Shares			Weighted avg. exercise price
	Balance, December 31, 2011			22,000		$	99.8
	2012
	Granted			-			-
	Cancelled			-			-
	Balance, December 31, 2012			22,000		$	99.8
	2013
	Granted			-			-
	Cancelled			(1,000	)		893.69
	Balance, December 31, 2013			21,000		$	28.4
	Warrants granted to non-employees outstanding at December 31, 2013 are summarized as follows:
	Description		Shares			Weighted Average
						Exercise Price
	Warrants issued in connection with equity offering			17,145,772		$	0.63
	Warrants issued in connection with debt agreement			450,000			0.58
	Warrants issued for services			264,386			2.64
				17,860,158		$	0.66
	No warrants were granted to non-employees for services in 2013. We granted 80,600 warrants to non-employees for services during the year ended December 31, 2012, with a weighted average exercise price of $3.00.
	Share-based compensation expense relating to stock options and warrants granted to non-employees amounted to $24,000 and $91,000 for the years ended December 31, 2013 and 2012, respectively.
	Common Stock
	During 2013 and 2012, we issued 0 and 2,500 shares of common stock, respectively, for consulting services valued at $0 and $4,000, respectively. Generally, these costs are amortized to share-based expense on a straight-line basis over the related service periods, generally ranging from six months to one year. Share-based compensation expense relating to all common stock issued for consulting services was $0 and $272,000 for the years ended December 31, 2013 and 2012, respectively.
	Employee Stock Purchase Plan
	Our qualified employee stock purchase plan (ESPP), approved by our Board of Directors and shareholders and adopted in June 2006, provides that eligible employees (employed at least 90 days) have the option to purchase shares of our common stock at a price equal to 85% of the lesser of the fair market value as of the first day or the last day of each offering period. Purchase options are granted semi-annually and are limited to the number of whole shares that can be purchased by an amount equal to up to 10% of a participant’s annual base salary. As of December 31, 2013, there were no shares of our common stock issued pursuant to the ESPP. There was no share-based compensation expense relating to the ESPP for the years ended December 31, 2013 and 2012, respectively.

Note_11_Segment_Information

Note 11 - Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 11.  Segment Information
	We manage and report our operations through two business segments: healthcare services and license and management services. We evaluate segment performance based on total assets, revenue and income or loss before provision for income taxes. Our assets are included within each discrete reporting segment. In the event that any services are provided to one reporting segment by the other, the transactions are valued at the market price. No such services were provided during the years ended December 31, 2013 and 2012.
	Healthcare Services
	Catasys’s integrated substance dependence solutions combine innovative medical and psychosocial treatments with elements of traditional disease management, case management, and ongoing member support to help organizations treat and manage substance dependent populations to impact both the medical and behavioral health costs associated with substance dependence and the related co-morbidities.
	We are currently marketing our integrated substance dependence solutions to managed care health plans on a case rate, monthly fee basis, or fee-for-service basis, which involves educating third party payors on the disproportionately high cost of their substance dependent population and demonstrating the potential for improved clinical outcomes and reduced cost associated with using our Catasys programs. We are operating out program in Kansas, Massachusetts, Louisiana, Oklahoma, Kentucky, West Virginia, and Wisconsin.
	License and Management
	Our license and management services segment primarily represents our managed treatment office, which offers a range of addiction treatment and mental health services.
	Summary financial information for our two reportable segments is as follows:
	(in thousands)	Twelve Months Ended December 31,
		2013			2012
	Healthcare services
	Revenues	$	754		$	375
	Income (loss) before provision for income taxes	$	(2,915	)	$	(9,752	)
	Assets *		2,451			3,846
	License and management services
	Revenues	$	112		$	166
	Loss before provision for income taxes	$	(1,755	)	$	(1,896	)
	Assets *		172			1,088
	Consolidated continuing operations
	Revenues	$	866		$	541
	Income (loss) before provision for income taxes	$	(4,670	)	$	(11,648	)
	Assets *		2,623			4,934
	* Assets are reported as of December 31.

Note_12_Commitments_and_Contin

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 12.  Commitments and Contingencies
	Operating Lease Commitments
	We incurred rent expense of approximately $294,000 and $290,000 for the years ended December 31, 2013 and 2012, respectively.
	Our principal executive and administrative offices are located in Los Angeles, California and consist of leased
	office space totaling approximately 9,076 square feet. The initial term of the lease expires in April 2019. Our base rent is currently approximately $29,000 per month, subject to annual adjustments.
	We had a related party receivable from Xoftek, Inc. in the amount of $115,000 as of December 31, 2013, which represents unpaid monthly rent related to a January 1, 2011 sublease agreement. We offset a $186,000 payable due to our Chairman and Chief Executive Officer against this receivable at December 31, 2013.
	Rent expense is calculated using the straight-line method based on the total minimum lease payments over the initial term of the lease. Landlord tenant improvement allowances and rent expense exceeding actual rent payments are accounted for as deferred rent liability in the balance sheet and amortized on a straight-line basis over the initial term of the respective leases.
	Future minimum payments, by year and in the aggregate, under non-cancelable operating leases with initial or remaining terms of one year or more, consist of the following at December 31, 2013:
	(In thousands)
	Year	Amount
	2014	$	215
	2015	$	354
	2016	$	365
	2017	$	376
	2018	$	387
	2019	$	99
	Clinical Research Commitments
	In prior years, we committed to unrestricted grants for clinical research study in the amount of $400,000, payable based on achieving certain milestones. As of December 31, 2013, we had approximately $356,000 remaining commitment for that clinical research study.
	Legal Proceedings
	As of the date of this report, we are not currently involved in any legal proceeding that we believe has a material adverse effect on our business, financial condition or operating results. We are however involved in litigation (“Isaka Matter”) as described below.
	On or about August 18, 2006, plaintiffs Isaka Investments, Ltd., Sand Hill Capital International Inc. and Richbourg Financial, Ltd. (“Plaintiffs”) filed a complaint in the Los Angeles Superior Court, entitled Isaka Investments, Ltd., Sand Hill Capital International, Inc. and Richbourg Financial, Ltd. vs. Xino Corporation, an entity from which our Company had acquired certain assets, and a number of other additional individuals and entities, including our Company, our Company’s Chairman and Chief Executive Officer, Terren S. Peizer, and other members of the Company’s Board of Directors. The Board of Directors and other parties were dismissed by way of demurrer. In July 2007, Plaintiffs filed their second amended complaint, asserting causes of action for conversion, a request for an order to set aside an alleged fraudulent conveyance and breach of contract against our Company, Mr. Peizer, and others.  In August 2007, our Company and Mr. Peizer, among others, filed an answer to the second amended complaint denying liability and asserting numerous affirmative defenses.  In June 2008, our Company, Mr. Peizer, and others, filed a motion for summary judgment, or alternatively, summary adjudication, and in October 2008, the Court granted summary adjudication as to each cause of action and consequently summary judgment in favor of our Company and Mr. Peizer, among others.  Plaintiffs appealed the summary judgment and in October 2010, the Court of Appeal reversed the trial court’s ruling.  The Court of Appeal’s decision was not on the merits, but rather provides that there are sufficient material issues of fact for the case to be tried.  The Court of Appeal issued a remittitur in December 2010, and Plaintiffs filed a motion for leave to amend the second amended complaint, which was granted in June 2011.  In June 2011, Plaintiffs filed their third amended complaint and, in August 2011, in response to a demurrer filed by the Company, Mr. Peizer and others, the Court held that Plaintiffs' third amended complaint was not pled with sufficient specificity to state the causes of action alleged therein.  In September 2011, Plaintiffs filed a fourth amended complaint, alleging causes of action for breach of fiduciary duty, fraudulent transfer, conversion, fraud, breach of contract, unfair business practices and wrongful interference with contractual relations and prospective business advantage.  The Company filed a demurrer related to the fourth amended complaint in September 2011.  At the hearing, the Court sustained, without leave to amend, the demurrers to the causes of action for breach of fiduciary duty and wrongful interference with contractual relations and prospective business advantage.  In October 2011, the Company, Mr. Peizer and others, filed an answer to the fourth amended complaint, denying liability and asserting numerous affirmative defenses.  In April 2012, the Court conducted a bench trial on the issue of whether the Plaintiffs have standing to pursue the causes of action alleged in their Fourth Amended Complaint other than the causes of action for conversion and breach of contract. At the conclusion of the trial, the Court ruled that Plaintiffs lack standing to pursue any causes of action other than for conversion and breach of contract. A Statement of Decision and Order of Dismissal was signed by the Court on July 18, 2012. Thereafter, the Plaintiffs filed an ex parte application to reopen the evidence which was denied by the Court. The Plaintiffs also filed a motion to amend their complaint seeking to add back in the claims that they lost at trial. The motion to amend was denied. On July 3, 2012, September 5, 2012 and October 15, 2012, the Plaintiffs filed Petitions for Writs of Mandate in the Court of Appeal. The Writs were summarily denied by the Court of Appeal. On October 9, 2012, the Court commenced hearings regarding the trial of the conversion and breach of contract causes of action. On October 15, 2012, the parties, through their counsel of record, stipulated to a bench trial on the admissibility and enforceability of a 2007 settlement agreement between Xino Corporation and the Company (the "Settlement Agreement"). Thus, the parties submitted the issue to the Court for a bench trial to determine whether the Settlement Agreement was admissible and effective to bar the two remaining claims. The Court held that the Settlement Agreement was admissible and enforceable to release the remaining claims. Accordingly, judgment was entered for the Company on November 19, 2012.  Plaintiffs filed a notice of appeal on December 10, 2012.  The appeal was fully briefed and oral arguments were heard on December 11, 2013. On January 23, 2014, the Court of Appeals denied their appeal. On February 4, 2014 the Plaintiff’s filed a Petition for rehearing which was denied on February 24, 2014. On February 27, 2014 the Plaintiff’s filed a Petition of Review with the California Supreme Court. The Company has had very limited  settlement discussions and the Company believes Plaintiffs’ claims are without merit and intends to continuously, and vigorously, defend the case.
	The Company believes it will prevail, but a range of loss could not be determined, should it not prevail, but we believe it would not have a material adverse effect on our financial statements.

Note_13_Subsequent_Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 13.  Subsequent Events
	In January 2014, we entered into securities purchase agreements with several investors, including Crede III, relating to the sale and issuance of an aggregate of 1,724,141 shares of common stock, and warrants (the “January Warrants”) to purchase an aggregate of 1,724,141 shares of Common Stock at an exercise price of $0.58 per share for aggregate gross proceeds of approximately $1.0 million. The January Warrants expire in January 2019, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our Common Stock, or other security convertible into our Common Stock, for a per share price less than the exercise price of the January Warrants, the exercise price of the January Warrants will be reduced to such lower price, subject to customary exceptions.
	Among other things, the Agreements provide that in the event that the Company effectuates a reverse stock split of its Common Stock within 24 months of the closing date of the Offering (the “Reverse Split”) and the volume weighted average price (“VWAP”) of the Common Stock during the 20 trading days following the effective date of the Reverse Split (the “VWAP Period”) declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company issue additional shares of Common Stock (the “Adjustment Shares"). The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of Common Stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of Common Stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.

Note_14_Restatement_of_Financi

Note 14 - Restatement of Financial Statements	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 14. Restatement of Financial Statements
	The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Basis of Consolidation and Presentation and Going Concern
	Our consolidated financial statements include the accounts of the company, our wholly-owned subsidiaries, and a managed professional medical corporation. Based on the provisions of the management service agreement between us and a medical corporation, we have determined that the medical corporation is a variable interest entity (VIE), and that we are the primary beneficiary as defined in the Financial Accounting Standards Board (FASB) rules for accounting for variable interest entities. Accordingly, we are required to consolidate the revenues and expenses of the managed medical corporation.
	Our financial statements have been prepared on the basis that we will continue as a going concern. At December 31, 2013, cash and cash equivalents amounted to $1.1 million and we had a working capital deficit of approximately $2.4 million. We have incurred significant operating losses and negative cash flows from operations since our inception. During the year ended December 31, 2013, our cash used in operating activities amounted $5.9 million. We anticipate continuing to incur negative cash flows and net losses for the next twelve months. The financial statements do not include any adjustments relating to the recoverability of the carrying amount of the recorded assets or the amount of liabilities that might result from the outcome of this uncertainty. As of December 31, 2013, these conditions raised substantial doubt as to our ability to continue as a going concern.
	Our ability to fund our ongoing operations and continue as a going concern is dependent on signing and generating fees from existing and new contracts for our Catasys managed care programs and the success of management’s plans to increase revenue and continue to control expenses. We are operating programs in Kansas, Massachusetts, Oklahoma, Louisiana, Kentucky, West Virginia, and Wisconsin. The programs in Kentucky and West Virginia commenced enrollment in the fourth quarter of 2013 and the Wisconsin program, which represents our first managed care Medicaid health plan customer, commenced enrollment in the first quarter of 2014. In March 2013, we signed an agreement with a national health plan to provide services to their members in New Jersey, which we expect to commence enrollment in the second quarter of 2014. We have generated fees from the launched programs and expect to increase enrollment and fees throughout 2014. However, there can be no assurance that we will generate such fees. In addition, we continue to seek ways to streamline our operating expenses.
	We and our Chief Executive Officer are party to a litigation in which the plaintiffs assert causes of action for conversion, a request for an order to set aside fraudulent conveyance and breach of contract. While the trial and appellate courts have ruled in our favor the plaintiff has filed a request to appeal to the state of Supreme Court. While we believe the plaintiffs’ claims are without merit and we intend to continue to vigorously defend the case, there can be no assurance that the litigation will ultimately be resolved in our favor. If this case is decided against us or our Chief Executive Officer, it may cause us to pay substantial damages, and other related fees. Regardless of whether this litigation is resolved in our favor, any lawsuit to which we are a party will likely be expensive and time consuming to defend or resolve. Costs of defense and any damages resulting from litigation, a ruling against us or a settlement of the litigation could have a significant negative impact our liquidity, including our cash flows.
	All inter-company transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts in the financial statements and disclosed in the accompanying notes. Significant areas requiring the use of management estimates include expense accruals, accounts receivable allowances, accrued claims payable, the useful life of depreciable and amortizable assets, the evaluation of asset impairment, the valuation of warrant liabilities, and shared-based compensation. Actual results could differ from those estimates.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Healthcare Services
	Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis based on enrolled members. To the extent our contracts may include a minimum performance guarantee, we reserve a portion of the monthly fees that may be at risk until the performance measurement period is completed. To the extent we receive case rates that are not subject to performance guarantees we recognize the case rate ratably over twelve months.
	License and Management Services
	Our license and management services revenues are derived from our managed treatment center, which we include in our consolidated financial statements, and which are derived from charging fees directly to patients for treatment and are recorded when services are provided. Revenues from patients treated with our proprietary treatment program are recorded based on the number of days of treatment completed during the period as a percentage of the total number treatment days for the treatment program.
Cost of Sales, Policy [Policy Text Block]	'
	Cost of Services
	Healthcare Services
	Cost of healthcare services consists primarily of salaries related to our care coaches, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Healthcare services cost of services is recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOnTrakTM database within the contracted timeframe, with all required billing elements correctly completed by the service provider.
	License and Management Services
	Cost of license and management services primarily represents direct costs associated with providing care to patients that are incurred in connection with our managed treatment center. Costs are recognized in the periods in which medical treatment is provided. Such costs include, but are not limited to, direct labor costs, medical supplies, and medications.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Compensation
	Our 2010 Stock Incentive Plan, as amended (“the Plan”), provides for the issuance of up to 1,825,000 shares of our common stock. Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than ten years from the date of grant and employee and board of director awards generally vest over three to five years. At December 31, 2013, we had an aggregate of 482,177 vested and unvested shares outstanding and 1,285,586 shares available for future awards.
	Total share-based compensation expense on a consolidated basis amounted to $213,000 and $2.2 million for the years ended December 31, 2013 and 2012, respectively.
	Stock Options – Employees and Directors
	We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.
	There were no new stock options granted during 2013. The estimated weighted average fair values of options granted during 2012 was $3.30 per share, and were calculated using the Black-Scholes pricing model based on the following assumptions:
		2012
	Expected volatility		151	%
	Risk-free interest rate		1.02	%
	Weighted average expected lives in years		6
	Expected dividend		0	%
	The expected volatility assumption for 2012 was based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected lives in years for 2012 reflect the application of the simplified method set out in Security and Exchange Commission (SEC) Staff Accounting Bulletin (SAB) 107 (and as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. We use historical data to estimate the rate of forfeitures assumption for awards granted to employees.
	We have elected to adopt the detailed method prescribed in FASB’s accounting rules for share-based compensation expense for calculating the beginning balance of the additional paid-in capital pool (APIC pool) related to the tax effects of employee share-based compensation, and to determine the subsequent impact on the APIC pool and consolidated statements of cash flows of the tax effects of employee share-based compensation awards that were outstanding upon adoption of such rules on January 1, 2006.
	Stock Options and Warrants – Non-employees
	We account for the issuance of stock options and warrants for services from non-employees by estimating the fair value of stock options and warrants issued using the Black-Scholes pricing model. This model’s calculations incorporate the exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, expected life of the option or warrant, expected volatility of our stock and expected dividends.
	For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.
	From time to time, we have retained terminated employees as part-time consultants upon their resignation from the company. Because the employees continue to provide services to us, their options continue to vest in accordance with the original terms. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards under FASB’s accounting rules for share-based expense but are instead accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. We recorded no expense during 2013 and 2012, respectively, associated with modified liability awards.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	We account for income taxes using the liability method in accordance with Accounting Standards Committee (“ASC”) 740 “Income Taxes” (formerly SFAS 109, “Accounting for Income Taxes”). To date, no current income tax liability has been recorded due to our accumulated net losses. Deferred tax assets and liabilities are recognized for temporary differences between the financial statement carrying amounts of assets and liabilities and the amounts that are reported in the tax returns. Deferred tax assets and liabilities are recorded on a net basis; however, our net deferred tax assets have been fully reserved by a valuation allowance due to the uncertainty of our ability to realize future taxable income and to recover our net deferred tax assets.
	In June 2006, the FASB issued FASB Interpretation No. 48 (FIN 48), “Accounting for Uncertainty in Income Taxes” (incorporated into ASC 740), which clarifies the accounting for uncertainty in income taxes. FIN 48 requires that companies recognize in the consolidated financial statements the impact of a tax position if that position is more likely than not of being sustained on audit based on the technical merits of the position. FIN 48 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. We adopted FIN 48 on January 1, 2007, with no impact to our consolidated financial statements.
Earnings Per Share, Policy [Policy Text Block]	'
	Basic and Diluted Loss per Share
	Basic loss per share is computed by dividing the net loss to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Basic and diluted loss per share has been adjusted retroactively for the 10-for-1 reverse stock split that occurred on May 6, 2013.
	Common equivalent shares, consisting of approximately 18,342,335 and 11,730,069 of incremental common shares as of December 31, 2013 and 2012, respectively, issuable upon the exercise of stock options and warrants, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Marketable Securities, Policy [Policy Text Block]	'
	Marketable Securities
	Investments include certificates of deposits with maturity dates greater than three months when purchased. These investments are classified as deposits, are reflected in long terms assets as part of deposits and other assets and are stated at fair market value.
	Our marketable securities consisted of investments with the following maturities as of December 31, 2013 and 2012:
	(in thousands)	Fair Market Value			Less than 1 Year		More than 10 Years
	Balance at December 31, 2012
	Certificates of deposit	$	175		$	175	$	-
	Balance at December 31, 2013
	Certificates of deposit	$	175		$	175	$	-
	The carrying value of all securities presented above approximated fair market value at December 31, 2013 and 2012, respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:
	Level Input:	Input Definition:
	Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
	Level II	Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
	Level III	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
	The following tables summarize fair value measurements by level at December 31, 2013 and 2012, respectively, for assets and liabilities measured at fair value on a recurring basis:
			Balance at December 31, 2012
	(Amounts in thousands)	Level I			Level II			Level III		Total
	Certificates of deposit		175			-			-		175
	Total assets		175			-			-		175
	Warrant liabilities		-			-			14,658		14,658
	Total liabilities		-			-			14,658		14,658
			Balance at December 31, 2013
	(Amounts in thousands)	Level I			Level II			Level III		Total
	Certificates of deposit		175			-			-		175
	Total assets		175			-			-		175
	Warrant liabilities		-			-			16,347		16,347
	Total liabilities		-			-			16,347		16,347
	We measure warrant liabilities issued from our debt and equity financings on a recurring basis. In accordance with current accounting rules, the warrant liabilities are being marked-to-market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes option pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. Significant increases (decreases) in any of these inputs could result in significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the expected term is accompanied by a change in the assumption used for the risk free rate and the expected stock. See Warrant Liabilities below.
	The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the years ended December 31, 2013 and 2012:
	(Dollars in thousands)	Level III Warrant Liabilities
	Balance as of December 31, 2011	$	4,528
	Change in fair value		(2,724	)
	Issuance of Warrants		12,854
	Balance as of December 31, 2012	$	14,658
	Reclassification to equity		(156	)
	Change in fair value		(5,392	)
	Issuance of Warrants		7,237
	Balance as of December 31, 2013	$	16,347
	Fair Value Information about Financial Instruments Not Measured at Fair Value
	FASB rules regarding fair value disclosures of financial instruments requires disclosure of fair value information about certain financial instruments for which it is practical to estimate that value.  The carrying amounts reported in our consolidated balance sheets for cash, cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments. There was no outstanding debt for the years ending December 31, 2013 and 2012, respectively. Considerable judgment is required to develop estimates of fair value.  Accordingly, the estimates are not necessarily indicative of the amounts we could realize in a current market exchange.  The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible Assets
	Intellectual Property
	Intellectual property consists primarily of the costs associated with acquiring certain technology, patents, patents pending, know-how and related intangible assets with respect to programs for treatment of dependence to alcohol, cocaine, methamphetamines other addictive stimulants, and anxiety. These long-term assets are stated at cost and are being amortized on a straight-line basis over the life of the respective patents, or patent applications, which is approximately seven years at December 31, 2013.
	Impairment of Long-Lived Assets
	Long-lived assets such as property, equipment and intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In reviewing for impairment, we compare the carrying value of such assets to the estimated undiscounted future cash flows expected from the use of the assets and their eventual disposition. When the estimated undiscounted future cash flows are less than their carrying amount, an impairment loss is recognized equal to the difference between the assets’ fair value and their carrying value.
	We performed an impairment analysis on intellectual property at December 31, 2013. For certain intangible assets, we considered numerous factors and we determined that the carrying value was not recoverable, and exceeded the fair-value. We recorded an impairment charge of $795,000 for these assets at December 31, 2013. We determined that the estimated lives of the remaining intellectual property properly reflected the current remaining economic lives of the assets.
	We performed an impairment analysis on intellectual property at December 31, 2012. For certain intangible assets, we considered numerous factors and we determined that the carrying value was not recoverable, and exceeded the fair-value. We recorded an impairment charge of $656,000 for these assets at December 31, 2012. We determined that the estimated lives of the remaining intellectual property properly reflected the current remaining economic lives of the assets.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years. Construction in progress is not depreciated until the related asset is placed into service.
Lease, Policy [Policy Text Block]	'
	Capital Leases
	Assets held under capital leases include computer equipment, and are recorded at the lower of the net present value of the minimum lease payments or the fair value of the leased asset at the inception of the lease. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. All lease agreements meet at least one of the four requirements of a capital lease in accordance with ASC 840 of the codification.
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	'
	Variable Interest Entities
	Generally, an entity is defined as a variable interest entity (VIE) under current accounting rules if it has (a) equity that is insufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (b) equity investors that cannot make significant decisions about the entity’s operations, or that do not absorb the expected losses or receive the expected returns of the entity. When determining whether an entity that is a business qualifies as a VIE, we also consider whether (i) we participated significantly in the design of the entity, (ii) we provided more than half of the total financial support to the entity, and (iii) substantially all of the activities of the VIE either involve us or are conducted on our behalf. A VIE is consolidated by its primary beneficiary, which is the party that absorbs or receives a majority of the entity’s expected losses or expected residual returns.
	As discussed under the heading Management Services Agreement below, we have an MSA with a managed medical corporation. Under this MSA, the equity owner of the affiliated medical group has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We participate significantly in the design of this MSA. We also agree to provide working capital loans to allow for the medical group to pay for its obligations. Substantially all of the activities of this managed medical corporation either involve us or are conducted for our benefit, as evidenced by the fact that under the MSA, we agree to provide and perform all non-medical management and administrative services for the medical group. Payment of our management fee is subordinate to payments of the obligations of the medical group, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated medical group or other third party. Creditors of the managed medical corporation do not have recourse to our general credit.
	Based on the design and provisions of this MSA and the working capital loan provided to the medical group, we have determined that the managed medical corporation is a VIE, and that we are the primary beneficiary as defined in current accounting rules. Accordingly, we are required to consolidate the revenues and expenses of such managed medical corporation.
Derivatives, Policy [Policy Text Block]	'
	Warrant Liabilities
	In April 2013, we entered into the securities purchase agreements with several investors, including Crede CG III, Ltd. (“Crede III”), an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and Shamus, LLC (“Shamus”) an affiliate of the Company, relating to the sale and issuance of an aggregate of 2,192,857 shares of common stock and warrants (the “April Warrants”) to purchase an aggregate of 2,192,857 shares of common stock at an exercise price of $0.70 per share for aggregate gross proceeds of approximately $1.5 million (the “April Offering”). The April Offering provides that in the event that we effectuate a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue the Adjustment Shares. We effectuated a reverse split on May 6, 2013, and no Adjustment Shares were issued.
	The April Warrants expire in April 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the April Warrants, the exercise price of the April Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the April Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period. In October 2013, we completed a private placement at $0.58 per share and the warrant shares associated with the April Offering were reduced to $0.58 per share.
	In October 2013, we entered into the securities and purchase agreements with several investors including Crede III and Shamus, relating to the sale and issuance of an aggregate of 4,550,002 shares of common stock and warrants (the “October Warrants”) to purchase an aggregate of 4,550,002 shares of common stock at an exercise price of $0.58 per share for aggregate gross proceeds of approximately $2.6 million (the “October Offering”). The October Offering provides that in the event that we effectuate a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue the Adjustment Shares.
	The October Warrants expire in October 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the October Warrants, the exercise price of the October Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the October Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
	In April 2012, we entered into security purchase agreements with several investors, including Crede III and David Smith, relating to the sale and issuance of an aggregate of 2,144,005shares of common stock and warrants (the “April 2012 Warrants”) to purchase an aggregate of 2,144,005 shares of common stock at an exercise price of $1.60 per share for aggregate gross proceeds of approximately $3,430,000 (the “April 2012 Offering”). The April 2012 Offering provide that in the event that the Company effectuates a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue the Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
	The April 2012 Warrants expire in April 2017, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the April 2012 Warrants, the exercise price of the April 2012 Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the April 2012 Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
	In May 2012, we entered into a securities purchase agreement with an accredited investor, on the same terms of the April 2012 Offering disclosed above, relating to the sale and issuance of 25,000 shares of common stock and warrants to purchase an aggregate of 25,000 shares of common stock at an exercise price of $1.60 per share, for gross proceeds of $40,000.
	In May 2012, we issued warrants to purchase an aggregate of 12,000 shares of common stock at an exercise price of $1.60 per share, associated with financing costs.
	In June 2012, we issued 6,250 restricted shares of common stock to a consultant for investor relation services to be performed beginning June 2012 and ending November 2012.
	In September 2012, we entered into securities purchase agreements with several investors including Crede III and David Smith, relating to the sale and issuance of an aggregate of 1,719,000 shares of the Company’s common stock and warrants (the “September Warrants”) to purchase an aggregate of 1,719,000 shares of common stock, at an exercise price of $1.00 per share, for aggregate gross proceeds of approximately $1.7 million (the “September Offering”). The foregoing issuances triggered anti-dilution provisions in certain of the Company’s outstanding warrants. As a result, the exercise price of these warrants decreased to $1.00 per share, however, the number of shares issuable under these warrants remained unchanged. The September Offering provide that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the September Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
	The September Warrants expire in September 2017, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the September Warrants, the exercise price of the September Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the September Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
	In December 2012, we entered into securities purchase agreements with several investors including Crede III and David Smith, relating to the sale and issuance of an aggregate of 4,712,143 shares of the Company’s common stock and warrants (the “December Warrants”) to purchase an aggregate of 4,712,143 shares of common stock, at an exercise price of $0.70 per share, for aggregate gross proceeds of approximately $3.3 million (the “December Offering”). The foregoing issuances triggered anti-dilution provisions in certain of the Company’s outstanding warrants. As a result, the exercise price of these warrants decreased to $0.70 per share, however, the number of shares issuable under these warrants remained unchanged. The December Offering provide that in the event that the Company effectuates a Reverse Split of its common stock within 24 months of the closing date of the December Offering and the VWAP of the common stock during the VWAP Period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company shall issue Adjustment Shares. The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of common stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such Investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of common stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.
	The December Warrants expire in December 2017, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the September Warrants, the exercise price of the September Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the December Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.
	We have issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, October 2013, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.
	For the years ended December 31, 2013 and 2012, we recognized a gain of $5.4 million and $2.7 million, respectively, related to the revaluation of our warrant liabilities.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	Financial instruments, which potentially subject us to a concentration of risk, include cash and accounts receivable. All of our customers are based in the United States at this time and we are not subject to exchange risk for accounts receivable.
	The Company maintains its cash in domestic financial institutions subject to insurance coverage issued by the Federal Deposit Insurance Corporation (FDIC). Under FDIC rules, the company is entitled to aggregate coverage as defined by the Federal regulation per account type per separate legal entity per financial institution. The Company has incurred no losses as a result of any credit risk exposures.
	For the year ended December 31, 2013, two customers accounted for approximately 76% of revenues and four customers accounted for approximately 91% of accounts receivable.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued or Newly Adopted Accounting Pronouncements
	In December 2011, the FASB issued Accounting Standards Update (“ASU”) No. 2011-11, Disclosures about Offsetting Assets and Liabilities (“ASU 2011-11”). The amendments in this update require enhanced disclosures around financial instruments and derivative instruments that are either (1) offset in accordance with either ASC 210-20-45 or ASC 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either ASC 210-20-45 or ASC 815-10-45. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The amendments are effective during interim and annual periods beginning after December 31, 2012. The adoption of ASU No. 2011-11 did not have a material effect on our consolidated financial statements or disclosures.
	In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-02”). ASU 2013-02 amends ASC 220, Comprehensive Income (“ASC 220”), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, (“ASU 2013-02”), which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. The adoption of ASU 2013-11 did not have a material effect on our consolidated financial position or results of operations.

Note_1_Summary_of_Significant_1

Note 1 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		2012
	Expected volatility		151	%
	Risk-free interest rate		1.02	%
	Weighted average expected lives in years		6
	Expected dividend		0	%
Investments Classified by Contractual Maturity Date [Table Text Block]	'
	(in thousands)	Fair Market Value			Less than 1 Year		More than 10 Years
	Balance at December 31, 2012
	Certificates of deposit	$	175		$	175	$	-
	Balance at December 31, 2013
	Certificates of deposit	$	175		$	175	$	-
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
			Balance at December 31, 2012
	(Amounts in thousands)	Level I			Level II			Level III		Total
	Certificates of deposit		175			-			-		175
	Total assets		175			-			-		175
	Warrant liabilities		-			-			14,658		14,658
	Total liabilities		-			-			14,658		14,658
			Balance at December 31, 2013
	(Amounts in thousands)	Level I			Level II			Level III		Total
	Certificates of deposit		175			-			-		175
	Total assets		175			-			-		175
	Warrant liabilities		-			-			16,347		16,347
	Total liabilities		-			-			16,347		16,347
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	(Dollars in thousands)	Level III Warrant Liabilities
	Balance as of December 31, 2011	$	4,528
	Change in fair value		(2,724	)
	Issuance of Warrants		12,854
	Balance as of December 31, 2012	$	14,658
	Reclassification to equity		(156	)
	Change in fair value		(5,392	)
	Issuance of Warrants		7,237
	Balance as of December 31, 2013	$	16,347

Note_2_Management_Services_Agr1

Note 2 - Management Services Agreements (Tables)	12 Months Ended
	Dec. 31, 2013
Management Services Agreements [Abstract]	'
Schedule of Variable Interest Entities [Table Text Block]	'
	(in thousands)	31-Dec-13		December 31, 2012
	Cash and cash equivalents	$	24	$	11
	Receivables, net		24		19
	Total assets	$	48		30
	Accounts payable		25		15
	Note payable to Catasys, Inc.		13,119		12,267
	Total liabilities	$	13,144		12,282

Note_3_Accounts_Receivable_Tab

Note 3 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
		December 31,
	(in thousands)	2013		2012
	Healthcare fees	$	146	$	50
	Patient fees receivable		24		19
	Other		3		-
	Total receivables	$	173	$	69
	Less allowance for doubtful accounts		-		-
	Total receivables, net	$	173	$	69

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	(in thousands)	2013			2012
	Furniture and equipment	$	2,054		$	3,169
	Leasehold improvements		313			1,558
	Total property and equipment		2,367			4,727
	Less accumulated depreciation and amortization		(2,001	)		(4,668	)
	Total property and equipment, net	$	366		$	59

Note_6_Intangible_Assets_Table

Note 6 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	(in thousands)	2013			2012
	Intellectual property	$	519		$	1,940
	Less accumulated amortization		(401	)		(892	)
	Total intangibles, net	$	118		$	1,048

Note_7_Capital_Lease_Obligatio1

Note 7 - Capital Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2013
Leases, Capital [Abstract]	'
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	(in thousands)	Amount
	Year ending December 31,
	2014	$	20
	2015		35
	2016		5
	Total minimum lease payments		60
	Less amounts representing interest		(9	)
	Capital lease obligations, net of interest		51
	Less current maturities of capital lease obligations		(25	)
	Long-term capital lease obligations	$	26

Note_8_Income_Taxes_Tables

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		2013			2012
	(in thousands)
	Federal, state and foreign net operating losses	$	68,199		$	66,120
	Stock based compensation		8,228			7,943
	Accrued liabilities		430			344
	Other temporary differences		(2,595	)		(2,668	)
	Valuation allowance		(74,262	)		(71,739	)
		$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		2013			2012
	Federal statutory rate		-34	%		-34	%
	State taxes, net of federal benefit		-37.1	%		2.8	%
	Non-deductible goodwill		0	%		0	%
	ISO / ESPP		1.3	%		4.5	%
	Other		0.4	%		-0.9	%
	Change in valuation allowance		69.6	%		27.6	%
	Tax provision		0.2	%		0	%

Note_10_Sharebased_Compensatio1

Note 10 - Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Note 10 - Share-based Compensation (Tables) [Line Items]	'
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
								Options Outstanding						Options Exercisable
		Range of Exercise Prices						Shares		Weighted Average Remaining Life (yrs)		Weighted Average Price		Shares		Weighted Average Price
		$0.00		to	$20.00				448,000		7.15	$	15.67		439,000	$	15.91
		$20.01		to	$1,000.00				13,000		4.83		154.03		13,000		154.03
									461,000		7.08	$	19.57		452,000	$	19.88
Schedule of Other Share-based Compensation, Activity [Table Text Block]	'
	Description		Shares			Weighted Average
						Exercise Price
	Warrants issued in connection with equity offering			17,145,772		$	0.63
	Warrants issued in connection with debt agreement			450,000			0.58
	Warrants issued for services			264,386			2.64
				17,860,158		$	0.66
Employee Stock Option [Member]	'
Note 10 - Share-based Compensation (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Shares			Weighted Avg. Exercise Price
	Balance, December 31, 2011			481,000		$	47.5
	2012
	Granted			8,000			3.3
	Cancelled/Expired			(3,000	)		46.2
	Balance, December 31, 2012			486,000		$	47.2
	2013
	Granted			-			-
	Cancelled/Expired			(25,000	)		151.7
	Balance, December 31, 2013			461,000		$	19.69
Stock Options And Warrants - Nonemployees [Member]	'
Note 10 - Share-based Compensation (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Shares			Weighted avg. exercise price
	Balance, December 31, 2011			22,000		$	99.8
	2012
	Granted			-			-
	Cancelled			-			-
	Balance, December 31, 2012			22,000		$	99.8
	2013
	Granted			-			-
	Cancelled			(1,000	)		893.69
	Balance, December 31, 2013			21,000		$	28.4

Note_11_Segment_Information_Ta

Note 11 - Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	(in thousands)	Twelve Months Ended December 31,
		2013			2012
	Healthcare services
	Revenues	$	754		$	375
	Income (loss) before provision for income taxes	$	(2,915	)	$	(9,752	)
	Assets *		2,451			3,846
	License and management services
	Revenues	$	112		$	166
	Loss before provision for income taxes	$	(1,755	)	$	(1,896	)
	Assets *		172			1,088
	Consolidated continuing operations
	Revenues	$	866		$	541
	Income (loss) before provision for income taxes	$	(4,670	)	$	(11,648	)
	Assets *		2,623			4,934
	* Assets are reported as of December 31.

Note_12_Commitments_and_Contin1

Note 12 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	(In thousands)
	Year	Amount
	2014	$	215
	2015	$	354
	2016	$	365
	2017	$	376
	2018	$	387
	2019	$	99

Note_1_Summary_of_Significant_2

Note 1 - Summary of Significant Accounting Policies (Details) (USD $)	1 Months Ended							2 Months Ended	12 Months Ended
	Oct. 31, 2013	Apr. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	31-May-12	Apr. 30, 2012	31-May-12	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of Operating Segments	'	'	'	'	'	'	'	'	2	'	'
Cash and Cash Equivalents, at Carrying Value (in Dollars)	'	'	$3,153,000	'	'	'	'	'	$1,136,000	$3,153,000	$771,000
Working Capital Deficit (in Dollars)	'	'	'	'	'	'	'	'	2,400,000	'	'
Net Cash Provided by (Used in) Operating Activities (in Dollars)	'	'	'	'	'	'	'	'	-5,935,000	-6,151,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	'	'	'	'	1,825,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	'	'	'	'	'	'	'	'	482,177	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	'	'	'	'	'	1,285,586	'	'
Allocated Share-based Compensation Expense (in Dollars)	'	'	'	'	'	'	'	'	213,000	2,200,000	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	'	'	'	'	'	'	18,342,335	11,730,069	'
Asset Impairment Charges (in Dollars)	'	'	'	'	'	'	'	'	795,000	656,000	'
Stock Issued During Period, Shares, New Issues	4,550,002	2,192,857	4,712,143	1,719,000	'	25,000	2,144,005	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,550,002	2,192,857	4,712,143	1,719,000	'	25,000	2,144,005	25,000	'	4,712,143	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	0.58	0.7	0.7	1	'	1.6	1.6	1.6	'	0.7	'
Proceeds from Issuance or Sale of Equity (in Dollars)	2,600,000	1,535,000	3,300,000	1,700,000	'	40,000	3,430,000	40,000	'	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	'	'	'	'	6,250	'	'	'	'	'	'
Derivative, Gain on Derivative (in Dollars)	'	'	'	'	'	'	'	'	$5,400,000	$2,700,000	'
Employees and Directors [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	'	'	'	'	'	'	'	'	'	3.3	'
April Warrant [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	0.58	'	'	'	'	'	'	'	'	'	'
October Warrant [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	0.58	'	'	'	'	'	'	'	'	'	'
Furniture and Equipment [Member] | Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'	'	'	'	'2 years	'	'
Furniture and Equipment [Member] | Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'	'	'	'	'7 years	'	'
Leasehold Improvements [Member] | Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'	'	'	'	'5 years	'	'
Leasehold Improvements [Member] | Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'	'	'	'	'7 years	'	'
Account Receivable [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	'	'	'	'	'	'	76.00%	'	'
Revenue [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	'	'	'	'	'	'	91.00%	'	'
2010 Stock Incentive Plan [Member] | Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'	'	'3 years	'	'
2010 Stock Incentive Plan [Member] | Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'	'	'5 years	'	'
Financing Costs [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	'	12,000	'	12,000	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	'	'	'	'	1.6	'	1.6	'	'	'
Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'	'	'6 months	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'	'	'	'	'7 years	'	'
Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'	'	'1 year	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'	'	'	'	'7 years	'	'

Note_1_Summary_of_Significant_3

Note 1 - Summary of Significant Accounting Policies (Details) - Black-Scholes Pricing Model	12 Months Ended
	Dec. 31, 2012
Black-Scholes Pricing Model [Abstract]	'
Expected volatility	151.00%
Risk-free interest rate	1.02%
Weighted average expected lives in years	'6 years
Expected dividend	0.00%

Note_1_Summary_of_Significant_4

Note 1 - Summary of Significant Accounting Policies (Details) - Maturities of Marketable Securities (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Maturities of Marketable Securities [Abstract]	'	'
Certificates of deposit	$175	$175
Certificates of deposit	$175	$175

Note_1_Summary_of_Significant_5

Note 1 - Summary of Significant Accounting Policies (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Note 1 - Summary of Significant Accounting Policies (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Certificates of deposit	$175	$175
Total assets	175	175
Warrant liabilities	16,347	14,658
Total liabilities	16,347	14,658
Fair Value, Inputs, Level 1 [Member]	'	'
Note 1 - Summary of Significant Accounting Policies (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Certificates of deposit	175	175
Total assets	175	175
Fair Value, Inputs, Level 3 [Member]	'	'
Note 1 - Summary of Significant Accounting Policies (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Warrant liabilities	16,347	14,658
Total liabilities	$16,347	$14,658

Note_1_Summary_of_Significant_6

Note 1 - Summary of Significant Accounting Policies (Details) - Fair Value Measurements Using Significant Level III Inputs (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements Using Significant Level III Inputs [Abstract]	'	'
Balance as of December 31, 2011	$14,658	$4,528
Balance	16,347	14,658
Reclassification to equity	-156	'
Change in Fair Value	-5,392	-2,724
Issuance of Warrants	$7,237	$12,854

Note_2_Management_Services_Agr2

Note 2 - Management Services Agreements (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Note 2 - Management Services Agreements (Details) [Line Items]	'	'
Debt Instrument, Basis Spread on Variable Rate	2.00%	'
Line of Credit Facility, Amount Outstanding (in Dollars)	$13.10	$12.30
Minimum [Member]	'	'
Note 2 - Management Services Agreements (Details) [Line Items]	'	'
Percent to Foregoing Cost	10.00%	'
Maximum [Member]	'	'
Note 2 - Management Services Agreements (Details) [Line Items]	'	'
Percent to Foregoing Cost	15.00%	'

Note_2_Management_Services_Agr3

Note 2 - Management Services Agreements (Details) - Amounts and Classification of Assets and Liabilities of the VIE (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Variable Interest Entity [Line Items]	'	'
Variable interest entity assets	$48	$30
Variable interest entity liabilities	13,144	12,282
Accounts Payable [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Variable interest entity liabilities	25	15
Note Payable [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Variable interest entity liabilities	13,119	12,267
Cash [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Variable interest entity assets	24	11
Receivables Net [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Variable interest entity assets	$24	$19

Note_3_Accounts_Receivable_Det

Note 3 - Accounts Receivable (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]	'	'
Allowance for Doubtful Accounts Receivable	$0	$0
Allowance for Doubtful Accounts Receivable, Write-offs	$9,000	$0

Note_3_Accounts_Receivable_Det1

Note 3 - Accounts Receivable (Details) - Accounts Receivables (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Receivables gross	$173	$69
Total receivables, net	173	69
Healthcare Fees [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Receivables gross	146	50
Patient Fees Receivable [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Receivables gross	24	19
Other Receivable [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Receivables gross	$3	'

Note_4_Receivable_Related_Part1

Note 4 - Receivable - Related Party (Details) (USD $)	12 Months Ended			12 Months Ended	1 Months Ended
	Dec. 31, 2013	Dec. 31, 2010	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2013
				Monthly Rent [Member]	Payments Received on Related Party Receivables [Member]
Note 4 - Receivable - Related Party (Details) [Line Items]	'	'	'	'	'
Operating Lease Term	'	'3 years	'	'	'
Related Party Transaction, Amounts of Transaction	'	'	'	$11,000	$267,000
Increase (Decrease) in Due to Related Parties	-186,000	'	'	'	'
Accounts Receivable, Related Parties	$115,000	'	$173,000	'	'

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation	$35,000	$73,000
Property, Plant and Equipment, Disposals	$2,700,000	'

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment (Details) - Property and Equipment (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property and Equipment [Abstract]	'	'
Furniture and equipment	$2,054	$3,169
Leasehold improvements	313	1,558
Total property and equipment	2,367	4,727
Less accumulated depreciation and amortization	-2,001	-4,668
Total property and equipment, net	$366	$59

Note_6_Intangible_Assets_Detai

Note 6 - Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 6 - Intangible Assets (Details) [Line Items]	'	'
Amortization of Intangible Assets	$135,000	$213,000
Amortization Expense Of Intellectual Property For Next Five Years	80,000	'
Other Asset Impairment Charges	$795,000	$656,000
Maximum [Member]	'	'
Note 6 - Intangible Assets (Details) [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'7 years	'

Note_6_Intangible_Assets_Detai1

Note 6 - Intangible Assets (Details) - Intellectual Property (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Intellectual Property [Abstract]	'	'
Intellectual property	$519	$1,940
Less accumulated amortization	-401	-892
Total intangibles, net	$118	$1,048

Note_7_Capital_Lease_Obligatio2

Note 7 - Capital Lease Obligations (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Leases, Capital [Abstract]	'	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Other Property, Plant, and Equipment, Gross	$64,000	$31,000
Capital Leases, Income Statement, Amortization Expense	$18,000	$4,000

Note_7_Capital_Lease_Obligatio3

Note 7 - Capital Lease Obligations (Details) - Future Minimum Lease Payments Required Under the Capital Leases (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Future Minimum Lease Payments Required Under the Capital Leases [Abstract]	'	'
2014	$20	'
2015	35	'
2016	5	'
Total minimum lease payments	60	'
Less amounts representing interest	-9	'
Capital lease obligations, net of interest	51	'
Less current maturities of capital lease obligations	-25	'
Long-term capital lease obligations	$26	$18

Note_8_Income_Taxes_Details

Note 8 - Income Taxes (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$172
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$169

Note_8_Income_Taxes_Details_Pr

Note 8 - Income Taxes (Details) - Primary Components of Net Deferred Tax Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Primary Components of Net Deferred Tax Assets [Abstract]	'	'
Federal, state and foreign net operating losses	$68,199	$66,120
Stock based compensation	8,228	7,943
Accrued liabilities	430	344
Other temporary differences	-2,595	-2,668
Valuation allowance	-74,262	-71,739
	$0	$0

Note_8_Income_Taxes_Details_Re

Note 8 - Income Taxes (Details) - Reconciliation Between the Statutory Federal Income Tax Rate and the Effective Income Tax Rate	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Reconciliation Between the Statutory Federal Income Tax Rate and the Effective Income Tax Rate [Abstract]	'	'
Federal statutory rate	-34.00%	-34.00%
State taxes, net of federal benefit	-37.10%	2.80%
Non-deductible goodwill	0.00%	0.00%
ISO / ESPP	1.30%	4.50%
Other	0.40%	-0.90%
Change in valuation allowance	69.60%	27.60%
Tax provision	0.20%	0.00%

Note_9_Equity_Financings_Detai

Note 9 - Equity Financings (Details) (USD $)	1 Months Ended						2 Months Ended
	Oct. 31, 2013	Apr. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	31-May-12	Apr. 30, 2012	31-May-12
Equity Financing [Abstract]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	4,550,002	2,192,857	4,712,143	1,719,000	25,000	2,144,005	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,550,002	2,192,857	4,712,143	1,719,000	25,000	2,144,005	25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	0.58	0.7	0.7	1	1.6	1.6	1.6
Proceeds from Issuance or Sale of Equity (in Dollars)	$2,600,000	$1,535,000	$3,300,000	$1,700,000	$40,000	$3,430,000	$40,000
Percentage of Shares Originally Purchased	20.00%	20.00%	20.00%	20.00%	'	20.00%	'

Note_10_Sharebased_Compensatio2

Note 10 - Share-based Compensation (Details) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

Oct. 31, 2013

Apr. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

31-May-12

Apr. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Stock Options - Employees And Directors [Member]

Stock Options - Employees And Directors [Member]

Stock Options - Employees And Directors [Member]

Stock Options And Warrants - Nonemployees [Member]

Stock Options And Warrants - Nonemployees [Member]

Issued For Consulting Services [Member]

Issued For Consulting Services [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Employee and Board of Directors [Member]

Employee and Board of Directors [Member]

Note 10 - Share-based Compensation (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

'

'

'

'

'

'

1,825,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Expiration Term

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'6 months

'5 years

'1 year

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)

'

'

'

'

'

'

482,177

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)

'

'

'

'

'

'

1,285,586

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation

'

'

'

'

'

'

$214,000

$2,190,000

$189,000

$1,800,000

'

$24,000

$91,000

$0

$272,000

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

'

'

'

'

'

'

0

80,600

'

8,000

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

$3.30

'

'

$3

'

'

'

'

'

'

'

'

Estimated Fair Value of Options Granted

'

'

'

'

'

'

'

'

'

24,294

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)

'

'

'

'

'

'

452,000

'

451,639

453,500

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)

'

'

'

'

'

'

$19.57

'

$20

$47.20

$47.50

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

'

'

'

'

'

'

'

'

44,000

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'

'

'1 year 18 days

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

80,600

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

4,550,002

2,192,857

4,712,143

1,719,000

25,000

2,144,005

'

'

'

'

'

'

'

0

2,500

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

'

'

'

'

0

417,000

'

'

'

'

'

0

4,000

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

$213,000

$2,200,000

'

'

'

'

'

'

'

$0

$0

'

'

'

'

Note_10_Sharebased_Compensatio3

Note 10 - Share-based Compensation (Details) - Stock Option Activity for Employee and Director Grants (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 10 - Share-based Compensation (Details) - Stock Option Activity for Employee and Director Grants [Line Items]	'	'	'
Balance	461,000	'	'
Balance	$19.57	'	'
Granted	0	80,600	'
Stock Options - Employees And Directors [Member]	'	'	'
Note 10 - Share-based Compensation (Details) - Stock Option Activity for Employee and Director Grants [Line Items]	'	'	'
Balance	461,000	486,000	481,000
Balance	$20	$47.20	$47.50
Granted	'	8,000	'
Granted	'	$3.30	'
Canceled	-25,000	-3,000	'
Canceled	$151.70	$46.20	'

Note_10_Sharebased_Compensatio4

Note 10 - Share-based Compensation (Details) - Options by Exercise Price Range (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding (in Shares)	461,000
Weighted Average Remaining Life of Options Outstanding	'7 years 29 days
Weighted Average Price of Options Outstanding	$19.57
Options Exercisable (in Shares)	452,000
Weighted Average Price of Options Exercisable	$19.88
Range One [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Lower Exercise Price Limit	$0
Upper Exercise Price Limit	$20
Options Outstanding (in Shares)	448,000
Weighted Average Remaining Life of Options Outstanding	'7 years 54 days
Weighted Average Price of Options Outstanding	$15.67
Options Exercisable (in Shares)	439,000
Weighted Average Price of Options Exercisable	$15.91
Range Three [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Lower Exercise Price Limit	$20.01
Upper Exercise Price Limit	$1,000
Options Outstanding (in Shares)	13,000
Weighted Average Remaining Life of Options Outstanding	'4 years 302 days
Weighted Average Price of Options Outstanding	$154.03
Options Exercisable (in Shares)	13,000
Weighted Average Price of Options Exercisable	$154.03

Note_10_Sharebased_Compensatio5

Note 10 - Share-based Compensation (Details) - Stock Option and Warrant Activity for Non-Employee Grants for Services (Stock Options And Warrants - Nonemployees [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options And Warrants - Nonemployees [Member]	'	'	'
Note 10 - Share-based Compensation (Details) - Stock Option and Warrant Activity for Non-Employee Grants for Services [Line Items]	'	'	'
Balance	21,000	22,000	22,000
Balance	$28.40	$99.80	$99.80
2012	'	'	'
Canceled	-1,000	'	'
Canceled	$893.69	'	'

Note_10_Sharebased_Compensatio6

Note 10 - Share-based Compensation (Details) - Stock Options and Warrants Granted to Non-Eployees for services outstanding (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 10 - Share-based Compensation (Details) - Stock Options and Warrants Granted to Non-Eployees for services outstanding [Line Items]	'	'	'
Warrants Issued	$16,347,000	$14,658,000	$4,528,000
Stock Options And Warrants - Nonemployees [Member] | Issued In Connection With Equity Offering [Member]	'	'	'
Note 10 - Share-based Compensation (Details) - Stock Options and Warrants Granted to Non-Eployees for services outstanding [Line Items]	'	'	'
Warrants Issued	17,145,772	'	'
Warrants Issued Weighted Average Exercise Price	$0.63	'	'
Stock Options And Warrants - Nonemployees [Member] | Issued In Connection With Debt Agreement [Member]	'	'	'
Note 10 - Share-based Compensation (Details) - Stock Options and Warrants Granted to Non-Eployees for services outstanding [Line Items]	'	'	'
Warrants Issued	450,000	'	'
Warrants Issued Weighted Average Exercise Price	$0.58	'	'
Stock Options And Warrants - Nonemployees [Member] | Issued For Services [Member]	'	'	'
Note 10 - Share-based Compensation (Details) - Stock Options and Warrants Granted to Non-Eployees for services outstanding [Line Items]	'	'	'
Warrants Issued	264,386	'	'
Warrants Issued Weighted Average Exercise Price	$2.64	'	'
Stock Options And Warrants - Nonemployees [Member]	'	'	'
Note 10 - Share-based Compensation (Details) - Stock Options and Warrants Granted to Non-Eployees for services outstanding [Line Items]	'	'	'
Warrants Issued	$17,860,158	'	'
Warrants Issued Weighted Average Exercise Price	$0.66	'	'

Note_11_Segment_Information_De

Note 11 - Segment Information (Details)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Number of Operating Segments	2
Number of Reportable Segments	1

Note_11_Segment_Information_De1

Note 11 - Segment Information (Details) - Segment Reporting Information, by Segment (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Healthcare services	'	'
Revenues	$754	$375
Revenues	112	166
Revenues	866	541
Income (Loss) before provision for income taxes	-4,670	-11,648
Assets	2,623	4,934
Healthcare Services [Member]	'	'
Healthcare services	'	'
Revenues	754	375
Income (Loss) before provision for income taxes	-2,915	-9,752
Assets	2,451	3,846
License and Management Services [Member]	'	'
Healthcare services	'	'
Revenues	112	166
Income (Loss) before provision for income taxes	-1,755	-1,896
Assets	$172	$1,088

Note_12_Commitments_and_Contin2

Note 12 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 12 - Commitments and Contingencies (Details) [Line Items]	'	'
Operating Leases, Rent Expense	$294,000	$290,000
Increase (Decrease) in Due to Related Parties	-186,000	'
Clinical Research Study Unrestricted Grants	400,000	'
Clinical Research Commitments [Member]	'	'
Note 12 - Commitments and Contingencies (Details) [Line Items]	'	'
Contractual Obligation	356,000	'
Xoftek, Inc. [Member]	'	'
Note 12 - Commitments and Contingencies (Details) [Line Items]	'	'
Due from Related Parties	115,000	'
Chairman and Chief Executive Officer [Member]	'	'
Note 12 - Commitments and Contingencies (Details) [Line Items]	'	'
Increase (Decrease) in Due to Related Parties	-186,000	'
Principal Executive And Administrative Offices [Member]	'	'
Note 12 - Commitments and Contingencies (Details) [Line Items]	'	'
Area of Real Estate Property (in Square Feet)	9,076	'
Rent Per Month	$29,000	'

Note_12_Commitments_and_Contin3

Note 12 - Commitments and Contingencies (Details) - Future Minimum Payments, Under Non-Cancelable Operating Leases (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Future Minimum Payments, Under Non-Cancelable Operating Leases [Abstract]	'
2014	$215
2015	354
2016	365
2017	376
2018	387
2019	$99

Note_13_Subsequent_Events_Deta

Note 13 - Subsequent Events (Details) (USD $)	1 Months Ended						2 Months Ended	1 Months Ended
	Oct. 31, 2013	Apr. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	31-May-12	Apr. 30, 2012	31-May-12	Jan. 31, 2014
								Subsequent Event [Member]
Note 13 - Subsequent Events (Details) [Line Items]	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	4,550,002	2,192,857	4,712,143	1,719,000	25,000	2,144,005	'	1,724,141
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,550,002	2,192,857	4,712,143	1,719,000	25,000	2,144,005	25,000	1,724,141
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	0.58	0.7	0.7	1	1.6	1.6	1.6	0.58
Proceeds from Issuance or Sale of Equity (in Dollars)	$2,600,000	$1,535,000	$3,300,000	$1,700,000	$40,000	$3,430,000	$40,000	$1,000,000
Percentage of Shares Originally Purchased	20.00%	20.00%	20.00%	20.00%	'	20.00%	'	20.00%

Note_14_Restatement_of_Financi1

Note 14 - Restatement of Financial Statements (Details)	0 Months Ended
	6-May-13
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity, Reverse Stock Split	'10-for-1